Content category

Guidelines - Pharmacovigilance

5 records

2025

2022

2021

Guidelines - Pharmacovigilance

4.4 : Post-Marketing Activities

21.0 Post-Marketing Activities 21.1 Pharmacovigilance 21.1.1 Reporting Adverse Drug Reaction (ADR) and Adverse Events Following Immunisation (AEFI) and Safety Updates 21.2 Post-Market Surveillance…

Document attached

Subscribe to Guidelines - Pharmacovigilance